28.05.2015
Formycon AG DE000A1EWVY8
DGAP-News: Formycon AG signs licensing agreement for its FYB203 biosimilar
Formycon AG / Key word(s): Miscellaneous
28.05.2015 07:02
Dissemination of a Corporate News, transmitted by DGAP - a service of EQS
Group AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
- Second biosimilar drug to be out-licensed from Formycon product pipeline
- Important milestone strengthens position as world's leading independent
biosimilars developer
- Formycon to receive success-based payments in the triple-digit millions
of euros
Munich - Formycon AG has announced the signing of an exclusive, global
out-licensing deal for its FYB203 biosimilar drug, with Santo Holding GmbH
as licensing partner. The newly signed agreement will ensure that Formycon
has project funding in place all the way through to market introduction.
Under the agreement, Santo Holding will assume responsibility for, and the
costs of, all further development activities, production and marketing of
the Formycon biosimilar drug. In return, Santo Holding will receive
exclusive worldwide marketing rights for FYB203. Pharmaceutical product
development through to regulatory approval will remain in the hands of
Formycon, while clinical development will be carried out by Bioeq GmbH,
which manages biosimilar product development activities on behalf of Santo
Holding. Under the terms of the new agreement, Formycon will receive an
immediate payment in the amount of several millions, along with ongoing
payment for its product development activities through to regulatory
approval. The company will, in addition, participate in sales revenue once
the project is brought to market, receiving a percentage share in the low
double digits. Based on sales projections, the agreement is thus expected
to yield Formycon total cumulative revenue well over the hundred million
euro mark.
"The signing of this important deal marks a further milestone for our
company as well as a major success for our entire team as we work to expand
our pipeline of biosimilars for the global market," declared Dr. Carsten
Brockmeyer, CEO of Formycon AG. "We are immensely pleased to have found
Santo Holding as a strong, ideal partner for our first two projects. Over
the past years, we have driven our company forward through our commitment
to investment in long-term research - and this is a strategy which we will
continue to relentlessly pursue."
"With the out-licensing deal for FYB203, we now have financing completely
in place for two biosimilar products, all the way through to market
launch," said Dr. Nicolas Combé, CFO of Formycon AG, in commenting on the
newly signed agreement. "For our shareholders, this means a project
financing expected to yield hundreds of millions of euros in revenue - and
without shareholder dilution. This is a resounding validation of our
strategy and, in particular, the superb work of our staff. The licensing
agreement further strengthens our financial flexibility as we work towards
our driving goal: to be the world's leading developer for the third wave of
biosimilar drugs."
"Biosimilar drugs are making an increasingly significant contribution to
patient care by making high-quality biopharmaceuticals accessible to them
at a fair price," added Nicola Mikulcik on behalf of Bioeq GmbH. "Based on
our successful work together on our first joint project, likewise bringing
this new product to market in partnership with Formycon is a logical step.
We anticipate excellent global market opportunities for both of these
products."
Formycon currently has three biosimilar drugs under development, with Santo
Holding its product partner for FYB201 and now also FYB203. The company
plans to develop the third product, FYB202, through to the end of phase I
clinical trials using its own resources.
Background: What are biosimilars?
Since their introduction in the 1980s, biopharmaceuticals have
revolutionized the treatment of diseases such as cancer, diabetes,
rheumatoid arthritis and multiple sclerosis. In the coming years, many of
the patents for these biotech drugs will expire - and by the year 2020,
medications with revenues of more than USD 100 billion will lose their
patent protection. In this way, it will become possible to launch new
competing drugs, known as "biosimilars". While the global market for these
new-generation drugs is currently some USD 2.5 billion, industry experts
expect this figure to grow tenfold by the year 2020. In contrast to
traditional generic drugs, the development and production of biosimilars is
highly complex and requires specialized expertise.
About Formycon:
Formycon AG is a leading independent developer of biosimilars for global
marketing and has become a recognized innovator in the field. The team of
the company which has today become Formycon AG has extensive experience in
the development of complex molecules. The company has already successfully
licensed two protein-based product portfolios out to major pharmaceutical
companies - in 2008 and 2011. Its specialist expertise allows the company
to develop high-quality biosimilars that meet the strict requirements of
the regulatory authorities in highly regulated countries and regions such
as Europe and the USA. Formycon currently has three biosimilar candidates
under development, the first of which has already been licensed out to
Santo Holding GmbH, with further product development projects in the
pipeline. Its aim is to be the first company in the world to present
clinical data for each respective product candidate and on this basis to
license these products out to major pharmaceutical and generics companies
for further development. Alternatively, Formycon offers further development
of its biosimilars all the way through to marketing authorization, as well
as commercial production on behalf of its licensees.
Contact:
Formycon AG
Fraunhoferstr. 15
82152 Martinsried/Planegg
Germany
phone +49 (0) 89 - 86 46 67 100
fax + 49 (0) 89 - 86 46 67 110
[email protected] // www.formycon.com
Disclaimer:
This release may contain forward-looking statements and information which
may be identified by formulations using terms such as "expects", "aims",
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or
"will". Such forward-looking statements are based on our current
expectations and certain assumptions which may be subject to variety of
risks and uncertainties. The results actually achieved by Formycon AG may
substantially differ from these forward-looking statements. Formycon AG
assumes no obligation to update these forward-looking statements or to
correct them in case of developments which differ from those anticipated.
28.05.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Formycon AG
Fraunhoferstraße 145
82152 Planegg-Martinsried
Germany
Phone: 089 864667 100
Fax: 089 864667 110
E-mail:
Internet: www.formycon.com
ISIN: DE000A1EWVY8
WKN: A1EWVY
Listed: Regulated Unofficial Market in Berlin; Open Market (Entry
Standard) in Frankfurt
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Formycon AG ISIN: DE000A1EWVY8 können Sie bei EQS abrufen
Biotechnologie , A1EWVY , FYB , XETR:FYB